Sandu Pharmaceuticals Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 764862, "name": "Sandu Pharma.", "stock_name": "Sandu Pharma.", "full_name": "Sandu Pharmaceuticals Ltd", "name_url": "stocks-analysis/sandu-pharma", "exchange": 0, "exchangecode": "", "primexch": 0, "country_id": 34, "currency": "INR", "cmp": "36.49", "chg": 0.23, "chgp": "0.63%", "dir": 1, "prev_price": "36.26", "mcapval": "36.00 Cr", "mcap": "Micro Cap", "scripcode": 524703, "symbol": "", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 49, "indexname": "India SENSEX", "isin": "INE751D01014", "curr_date": "Apr 10", "curr_time": "", "bse_nse_vol": "1.26 k", "exc_status": "Active", "traded_date": "Apr 10, 2026", "traded_date_str": "2026 04 10", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sandu-pharma-764862-0&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0 } }, "news": { "results": [ { "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3941430", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_mojoScore_3941430.png", "date": "2026-04-10 10:10:44", "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 Sep 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 10 April 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook." }, { "title": "Sandu Pharmaceuticals Ltd Valuation Shifts Signal Renewed Price Attractiveness", "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-signal-renewed-price-attractiveness-3933647", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SanduPharmaceut_valuationdot_3933647.png", "date": "2026-04-06 08:00:56", "description": "Sandu Pharmaceuticals Ltd has witnessed a notable shift in its valuation parameters, moving from a fair to an attractive rating, despite ongoing sector headwinds and a challenging market environment. This change, driven primarily by improvements in price-to-earnings and price-to-book value ratios, offers investors a fresh perspective on the stock’s price attractiveness relative to its historical and peer benchmarks." }, { "title": "Sandu Pharmaceuticals Declines 2.82% This Week: Key Factors Behind the Volatile Moves", "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-declines-282-this-week-key-factors-behind-the-volatile-moves-3932103", "imagepath": "", "date": "2026-04-04 16:01:10", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>30 Mar:</strong> Stock hits 52-week low at Rs.30.52 amid continued downtrend</p>\n <p><strong>1 Apr:</strong> Sharp recovery with 10.39% gain to Rs.33.69</p>\n <p><strong>2 Apr:</strong> Price retreats 3.77% to Rs.32.42</p>\n <p><strong>3 Apr:</strong> No trading data available</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.33.36</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">Week Close</div><div class=\"stat-value\">Rs.32.42</div><div class=\"stat-change negative\">-2.82%..." }, { "title": "Sandu Pharmaceuticals Ltd Falls to 52-Week Low of Rs 30 Amidst Persistent Downtrend", "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-falls-to-52-week-low-of-rs30-amidst-continued-downtrend-3925181", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SanduPharmaceut_priceRelatedfactors_3925181.png", "date": "2026-03-30 14:02:58", "description": "A sharp decline over the past two sessions has dragged Sandu Pharmaceuticals Ltd to a fresh 52-week low of Rs 30 on 30 Mar 2026, marking a significant 49% drop from its peak of Rs 58.8 within the last year. This downturn comes despite some pockets of financial improvement, highlighting a complex interplay of market sentiment and company fundamentals." }, { "title": "Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amidst Weak Market Performance", "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-to-fair-amidst-weak-market-performance-3923329", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SanduPharmaceut_valuationdot_3923329.png", "date": "2026-03-30 08:01:25", "description": "Sandu Pharmaceuticals Ltd has seen its valuation parameters adjust from attractive to fair, reflecting a nuanced shift in investor sentiment amid a challenging market backdrop. Despite a recent downgrade to a Strong Sell rating, the company’s price-to-earnings and price-to-book ratios suggest a more balanced valuation compared to its historical averages and peer group, signalling a complex investment case for stakeholders." }, { "title": "Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amidst Challenging Market Returns", "link": "https://www.marketsmojo.com/news/stocks-in-action/sandu-pharmaceuticals-ltd-valuation-shifts-to-fair-amidst-challenging-market-returns-3909052", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SanduPharmaceut_valuationdot_3909052.png", "date": "2026-03-24 08:01:25", "description": "Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair price range. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, warrants a detailed analysis to understand its implications for investors amid a challenging market backdrop." }, { "title": "Why is Sandu Pharmaceuticals Ltd falling/rising?", "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-sandu-pharmaceuticals-ltd-fallingrising-3890367", "imagepath": "", "date": "2026-03-14 01:14:32", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Recent Price Movement and Market Context</strong></p>\n<p>Sandu Pharmaceuticals has been on a downward trajectory over the past fortnight, with the stock falling 5.38% in the last week, closely mirroring the Sensex’s decline of 5.52%. Over the past month, the stock’s performance remains weak, down 5.46%, although it has outperformed the Sensex’s sharper 9.76% fall during the same period. Year-to-date, the stock has declined 12.10%, slightly better than the Sensex’s 12.50% drop, but the longer-term trend is more concerning. Over one year, Sandu Pharmaceuticals has plummeted 36.85%, in stark contrast to the Sensex’s modest 1.00% gain. The three-year and five-year returns further highlight the stock’s underperformance, with losses of 42.29% over three years compared to the Sensex’s 28.03% gain, ..." }, { "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3846819", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SanduPharmaceut_mojoScore_3846819.png", "date": "2026-02-19 10:10:26", "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed below reflect the stock's current position as of 19 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook." }, { "title": "Sandu Pharmaceuticals Ltd is Rated Strong Sell", "link": "https://www.marketsmojo.com/news/stock-recommendation/sandu-pharmaceuticals-ltd-is-rated-strong-sell-3825794", "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/SanduPharmaceut_mojoScore_3825794.png", "date": "2026-02-07 10:10:19", "description": "Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 February 2026, providing investors with an up-to-date view of the company’s performance and outlook." } ], "total": 92, "sid": "764862", "stock_news_url": "https://www.marketsmojo.com/news/sandu-pharmaceuticals-764862" }, "announcements": [ { "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018", "datetime": "07-Apr-2026", "details": "Certificate under Regulation 74(5) of SEBI(DP) Regulation 2018 for Q ended 31st March 2026", "source": "BSE" }, { "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication", "datetime": "04-Apr-2026", "details": "Newspaper Publication regarding - second 100 days Campaign Saksham Niveshak and Special Window for Transfer and Dematerialisation of Physical Securities", "source": "BSE" }, { "caption": "Closure of Trading Window", "datetime": "21-Mar-2026", "details": "Intimation about closure of Trading Window for Q ended 31st March 2026", "source": "BSE" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Sandu Pharmaceuticals Ltd has declared <strong>8%</strong> dividend, ex-date: 18 Sep 25", "dt": "2025-09-18", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "No <strong>Splits</strong> history available", "data": [] }, { "img": "bonus.svg", "title": "BONUS", "msg": "No <strong>Bonus</strong> history available", "data": [] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Key Events This Week

30 Mar: Stock hits 52-week low at Rs.30.52 amid continued downtrend

1 Apr: Sharp recovery with 10.39% gain to Rs.33.69

2 Apr: Price retreats 3.77% to Rs.32.42

3 Apr: No trading data available

Read full news article

Sandu Pharmaceuticals Ltd Falls to 52-Week Low of Rs 30 Amidst Persistent Downtrend

2026-03-30 14:02:58

A sharp decline over the past two sessions has dragged Sandu Pharmaceuticals Ltd to a fresh 52-week low of Rs 30 on 30 Mar 2026, marking a significant 49% drop from its peak of Rs 58.8 within the last year. This downturn comes despite some pockets of financial improvement, highlighting a complex interplay of market sentiment and company fundamentals.

Read full news article

Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amidst Weak Market Performance

2026-03-30 08:01:25

Sandu Pharmaceuticals Ltd has seen its valuation parameters adjust from attractive to fair, reflecting a nuanced shift in investor sentiment amid a challenging market backdrop. Despite a recent downgrade to a Strong Sell rating, the company’s price-to-earnings and price-to-book ratios suggest a more balanced valuation compared to its historical averages and peer group, signalling a complex investment case for stakeholders.

Read full news article

Sandu Pharmaceuticals Ltd Valuation Shifts to Fair Amidst Challenging Market Returns

2026-03-24 08:01:25

Sandu Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its valuation parameters, moving from an attractive to a fair price range. This change, reflected in key metrics such as the price-to-earnings (P/E) and price-to-book value (P/BV) ratios, warrants a detailed analysis to understand its implications for investors amid a challenging market backdrop.

Read full news article

Why is Sandu Pharmaceuticals Ltd falling/rising?

2026-03-14 01:14:32

Recent Price Movement and Market Context

Sandu Pharmaceuticals has been on a downward trajectory over the past fortnight, with the stock falling 5.38% in the last week, closely mirroring the Sensex’s decline of 5.52%. Over the past month, the stock’s performance remains weak, down 5.46%, although it has outperformed the Sensex’s sharper 9.76% fall during the same period. Year-to-date, the stock has declined 12.10%, slightly better than the Sensex’s 12.50% drop, but the longer-term trend is more concerning. Over one year, Sandu Pharmaceuticals has plummeted 36.85%, in stark contrast to the Sensex’s modest 1.00% gain. The three-year and five-year returns further highlight the stock’s underperformance, with losses of 42.29% over three years compared to the Sensex’s 28.03% gain, ...

Read full news article

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2026-02-19 10:10:26

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed below reflect the stock's current position as of 19 February 2026, providing investors with an up-to-date perspective on the company’s performance and outlook.

Read full news article

Sandu Pharmaceuticals Ltd is Rated Strong Sell

2026-02-07 10:10:19

Sandu Pharmaceuticals Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 19 September 2024. However, the analysis and financial metrics discussed here reflect the stock's current position as of 07 February 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Read full news article

View All News